Using the adenoviral vectored vaccine platform for bacterial infections
Professor Christine Rollier (University of Surrey)
Monday, 03 March 2025, 1pm to 2pm
BDI/OxPop Building LG seminar rooms
Abstract
With the recent success of adenoviral vaccines against Ebola and SARS-CoV-2, the potential of this platform in the fight against outbreak pathogens is being realized for human infectious diseases. This technology is suitable for large scale manufacture and relatively low cost. The potential of viral-vectors to induce T Helper type 1 and high antibody responses makes the use of this approach attractive in efforts to combat the disease and disability caused by viral pathogens. However, the case for their use in bacterial vaccines is less clear: the expression of a bacterial protein in a eukaryotic cell may impact on the antigen localization, induce unwanted glycosylation or affect protein conformation, and this is also true if using the mRNA vaccine platform. The potential and challenges of adenoviral vectors was explored against two bacterial diseases. While our work highlights the challenges inherent in developing novel vaccines using this technology and can be applied to mRNA, the successful progression of two novel bacterial vaccines to clinical development underlines the potential of these platforms for vaccine development against bacterial diseases, and their potential for veterinary use.
University members only.
VIEW Previous Richard Doll seminars IN Public health and epidemiology
Professor Sir Richard Doll
Forthcoming events
Will the next pandemic be caused by H5N1 influenza?
Monday, 02 June 2025, 1pm to 2pm @ Richard Doll Lecture Theatre
The world is currently experiencing a panzootic of H5N1 influenza. Wild birds have carried the virus across all continents and an unprecedented number of mammalian species have been infected including humans. What will it take for this virus to go pandemic, and does the introduction of the virus into dairy herds in USA bring that one step closer? Wendy will discuss the current knowledge on host range barriers that protect us from more frequent zoonoses and pandemic from bird flu, and show how we can use this scientific knowledge to risk assess the current situation.
Trials and tribulations: streamlining large randomized trials to answer important cardiometabolic questions
Tuesday, 03 June 2025, 1pm to 2pm @ Richard Doll lecture theatre
Better treatment for tuberculosis
Monday, 09 June 2025, 1pm to 2pm @ BDI/OxPop Building LG seminar rooms
Resolving the genetic basis of type 2 diabetes in 125 000 Mexicans
Tuesday, 10 June 2025, 1pm to 2pm @ Richard Doll Lecture Theatre
The burden of drug resistant infections, the GRAM project
Monday, 16 June 2025, 1pm to 2pm @ BDI/OxPop Building LG seminar rooms
Large scale genetic consortia
Tuesday, 17 June 2025, 1pm to 2pm @ Richard Doll lecture theatre